ADCTADC Therapeutics SA
Pharmaceutical Preparations
- Revenue
- $81M
- 15% YoY
- Operating margin
- -149.3%
- 19% YoY
- EBITDA
- −$121M
- 6.6% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear8% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|
| Revenue | $75M | $69M | $71M | $81M | 15% |
| Operating income | −$123M | −$166M | −$131M | −$121M | 7.0% |
| Net income | −$157M | −$240M | −$158M | −$143M | 9.6% |
| Operating cash flow | −$138M | −$119M | −$124M | −$141M | 14% |
| Capex | $687K | $3M | $867K | $264K | 70% |
| Stock-based comp | $49M | $13M | $7M | $7M | 5.1% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $2M | $6M | 92 | — |
| FY2024 | $2M | $4M | 52 | — |
| FY2023 | $4M | $3M | 43 | — |